Direct and indirect pathways of basal ganglia: a critical reappraisal

The basal ganglia are subcortical nuclei controlling voluntary actions and have been implicated in Parkinson's disease (PD). The prevailing model of basal ganglia function states that two circuits, the direct and indirect pathways, originate from distinct populations of striatal medium spiny neurons (MSNs) and project to different output structures. These circuits are believed to have opposite effects on movement. Specifically, the activity of direct pathway MSNs is postulated to promote movement, whereas the activation of indirect pathway MSNs is hypothesized to inhibit it. Recent findings have revealed that this model might not fully account for the concurrent activation of both pathways during movement. Accordingly, we propose a model in which intrastriatal connections are critical and the two pathways are structurally and functionally intertwined. Thus, all MSNs might either facilitate or inhibit movement depending on the form of synaptic plasticity expressed at a certain moment. In PD, alterations of dopamine-dependent synaptic plasticity could alter this coordinated activity.

[1]  T. Pasik,et al.  A Golgi study of neuronal types in the neostriatum of monkeys , 1976, Brain Research.

[2]  J. Bouyer,et al.  Chemical and structural analysis of the relation between cortical inputs and tyrosine hydroxylase-containing terminals in rat neostriatum , 1984, Brain Research.

[3]  R. Ferrante,et al.  Neuropathological Classification of Huntington's Disease , 1985, Journal of neuropathology and experimental neurology.

[4]  A. D. Smith,et al.  Identification of synaptic terminals of thalamic or cortical origin in contact with distinct medium‐size spiny neurons in the rat neostriatum , 1988, The Journal of comparative neurology.

[5]  J. Penney,et al.  The functional anatomy of basal ganglia disorders , 1989, Trends in Neurosciences.

[6]  C. Wilson,et al.  Intracellular recording of identified neostriatal patch and matrix spiny cells in a slice preparation preserving cortical inputs. , 1989, Journal of neurophysiology.

[7]  M. Delong,et al.  Primate models of movement disorders of basal ganglia origin , 1990, Trends in Neurosciences.

[8]  H. Bergman,et al.  Reversal of experimental parkinsonism by lesions of the subthalamic nucleus. , 1990, Science.

[9]  C. Gerfen,et al.  D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. , 1990, Science.

[10]  C. Wilson,et al.  Projection subtypes of rat neostriatal matrix cells revealed by intracellular injection of biocytin , 1990, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[11]  T. Aziz,et al.  Lesion of the subthalamic nucleus for the alleviation of 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP)‐induced parkinsonism in the primate , 1991, Movement disorders : official journal of the Movement Disorder Society.

[12]  S. Sesack,et al.  Cellular basis for interactions between catecholaminergic afferents and neurons containing leu‐enkephalin‐like immunoreactivity in rat caudate‐putamen nuclei , 1992, Journal of neuroscience research.

[13]  P. Calabresi,et al.  Coactivation of D1 and D2 dopamine receptors is required for long-term synaptic depression in the striatum , 1992, Neuroscience Letters.

[14]  P. Calabresi,et al.  Long-term synaptic depression in the striatum: physiological and pharmacological characterization , 1992, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[15]  J. Bolam,et al.  Input from the frontal cortex and the parafascicular nucleus to cholinergic interneurons in the dorsal striatum of the rat , 1992, Neuroscience.

[16]  D. Lovinger,et al.  Short- and long-term synaptic depression in rat neostriatum. , 1993, Journal of neurophysiology.

[17]  Charles J. Wilson,et al.  Striatal interneurones: chemical, physiological and morphological characterization , 1995, Trends in Neurosciences.

[18]  D. Pinault,et al.  Single striatofugal axons arborizing in both pallidal segments and in the substantia nigra in primates , 1995, Brain Research.

[19]  A. Lang,et al.  Posteroventral medial pallidotomy in advanced Parkinson's disease. , 1997, Advances in neurology.

[20]  P. Calabresi,et al.  A Critical Role of the Nitric Oxide/cGMP Pathway in Corticostriatal Long-Term Depression , 1999, The Journal of Neuroscience.

[21]  P. Greengard,et al.  Dopamine and cAMP-Regulated Phosphoprotein 32 kDa Controls Both Striatal Long-Term Depression and Long-Term Potentiation, Opposing Forms of Synaptic Plasticity , 2000, The Journal of Neuroscience.

[22]  J. Dostrovsky,et al.  Effects of apomorphine on subthalamic nucleus and globus pallidus internus neurons in patients with Parkinson's disease. , 2001, Journal of neurophysiology.

[23]  D. Lovinger,et al.  Postsynaptic endocannabinoid release is critical to long-term depression in the striatum , 2002, Nature Neuroscience.

[24]  P. Calabresi,et al.  Experimental Parkinsonism Alters Endocannabinoid Degradation: Implications for Striatal Glutamatergic Transmission , 2002, The Journal of Neuroscience.

[25]  David M. Lovinger,et al.  It could be habit forming: drugs of abuse and striatal synaptic plasticity , 2003, Trends in Neurosciences.

[26]  Klaus Mewes,et al.  Randomized trial of pallidotomy versus medical therapy for Parkinson's disease , 2003, Annals of neurology.

[27]  P. Calabresi,et al.  Levodopa treatment reverses endocannabinoid system abnormalities in experimental parkinsonism , 2003, Journal of neurochemistry.

[28]  D. Lovinger,et al.  Disruption of Endocannabinoid Release and Striatal Long-Term Depression by Postsynaptic Blockade of Endocannabinoid Membrane Transport , 2004, The Journal of Neuroscience.

[29]  G. Bernardi,et al.  The 'magic' of L-dopa: why is it the gold standard Parkinson's disease therapy? , 2005, Trends in pharmacological sciences.

[30]  A. Parent,et al.  The striatofugal fiber system in primates: a reevaluation of its organization based on single-axon tracing studies. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[31]  I Litvan,et al.  Bilateral subthalamotomy in Parkinson's disease: initial and long-term response. , 2005, Brain : a journal of neurology.

[32]  A. Sanabria,et al.  Randomized controlled trial. , 2005, World journal of surgery.

[33]  Rui M. Costa,et al.  Rapid Alterations in Corticostriatal Ensemble Coordination during Acute Dopamine-Dependent Motor Dysfunction , 2006, Neuron.

[34]  Kae Nakamura,et al.  Basal ganglia orient eyes to reward. , 2006, Journal of neurophysiology.

[35]  Erwan Bezard,et al.  Phenotype of Striatofugal Medium Spiny Neurons in Parkinsonian and Dyskinetic Nonhuman Primates: A Call for a Reappraisal of the Functional Organization of the Basal Ganglia , 2006, The Journal of Neuroscience.

[36]  D. Lovinger,et al.  Frequency-specific and D2 receptor-mediated inhibition of glutamate release by retrograde endocannabinoid signaling. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[37]  S. Fahn,et al.  Levodopa in the treatment of Parkinson's disease: A consensus meeting viewpoint , 1999, Movement disorders : official journal of the Movement Disorder Society.

[38]  A. Reiner,et al.  Differential perikaryal localization in rats of D1 and D2 dopamine receptors on striatal projection neuron types identified by retrograde labeling , 2006, Journal of Chemical Neuroanatomy.

[39]  Henry H. Yin,et al.  Dopaminergic Control of Corticostriatal Long-Term Synaptic Depression in Medium Spiny Neurons Is Mediated by Cholinergic Interneurons , 2006, Neuron.

[40]  A. Sampson,et al.  Selective elimination of glutamatergic synapses on striatopallidal neurons in Parkinson disease models , 2006, Nature Neuroscience.

[41]  Robert C. Malenka,et al.  Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson's disease models , 2007, Nature.

[42]  D. Lovinger,et al.  Retrograde endocannabinoid signaling at striatal synapses requires a regulated postsynaptic release step , 2007, Proceedings of the National Academy of Sciences.

[43]  Paolo Calabresi,et al.  Dopamine-mediated regulation of corticostriatal synaptic plasticity , 2007, Trends in Neurosciences.

[44]  H. Bergman,et al.  Pathological synchronization in Parkinson's disease: networks, models and treatments , 2007, Trends in Neurosciences.

[45]  Joshua L Plotkin,et al.  Differential Excitability and Modulation of Striatal Medium Spiny Neuron Dendrites , 2008, The Journal of Neuroscience.

[46]  Max Kleiman-Weiner,et al.  Differential electrophysiological properties of dopamine D1 and D2 receptor‐containing striatal medium‐sized spiny neurons , 2008, The European journal of neuroscience.

[47]  Valeria Della-Maggiore,et al.  Functional integration across a gradient of corticostriatal channels controls UP state transitions in the dorsal striatum , 2008, Proceedings of the National Academy of Sciences.

[48]  P. Calabresi,et al.  The endocannabinoid system in Parkinson's disease. , 2008, Current pharmaceutical design.

[49]  D. Surmeier,et al.  Dichotomous Anatomical Properties of Adult Striatal Medium Spiny Neurons , 2008, The Journal of Neuroscience.

[50]  P. Greengard,et al.  Dichotomous Dopaminergic Control of Striatal Synaptic Plasticity , 2008, Science.

[51]  E. Nestler,et al.  Neurotrophic factors and structural plasticity in addiction , 2009, Neuropharmacology.

[52]  S. Schiffmann,et al.  D2R striatopallidal neurons inhibit both locomotor and drug reward processes , 2009, Nature Neuroscience.

[53]  Erwan Bezard,et al.  Chronic dopaminergic stimulation in Parkinson's disease: from dyskinesias to impulse control disorders , 2009, The Lancet Neurology.

[54]  D. Lovinger,et al.  Endocannabinoid‐dependent plasticity at GABAergic and glutamatergic synapses in the striatum is regulated by synaptic activity , 2009, The European journal of neuroscience.

[55]  B. O'dowd,et al.  Calcium signaling cascade links dopamine D1–D2 receptor heteromer to striatal BDNF production and neuronal growth , 2009, Proceedings of the National Academy of Sciences.

[56]  G. Fisone,et al.  Looking BAC at striatal signaling: cell-specific analysis in new transgenic mice , 2009, Trends in Neurosciences.

[57]  N. Volkow,et al.  Neurocircuitry of Addiction , 2010, Neuropsychopharmacology.

[58]  Neuroscience: Brain's traffic lights , 2010, Nature.

[59]  J. Roiser,et al.  Reward and Punishment Processing in Depression , 2010, Biological Psychiatry.

[60]  S. Nakanishi,et al.  Distinct Roles of Synaptic Transmission in Direct and Indirect Striatal Pathways to Reward and Aversive Behavior , 2010, Neuron.

[61]  P. Krack,et al.  Deep brain stimulation: from neurology to psychiatry? , 2010, Trends in Neurosciences.

[62]  S. Vincent Nitric oxide neurons and neurotransmission , 2010, Progress in Neurobiology.

[63]  O. Rascol,et al.  Dopamine Receptor Agonists for the Treatment of Early or Advanced Parkinson’s Disease , 2010, CNS drugs.

[64]  G. Lynch,et al.  Presynaptic BDNF Promotes Postsynaptic Long-Term Potentiation in the Dorsal Striatum , 2010, The Journal of Neuroscience.

[65]  Xin Jin,et al.  Start/stop signals emerge in nigrostriatal circuits during sequence learning , 2010, Nature.

[66]  Paul Greengard,et al.  Distinct subclasses of medium spiny neurons differentially regulate striatal motor behaviors , 2010, Proceedings of the National Academy of Sciences.

[67]  P. Calabresi,et al.  Levodopa-induced dyskinesias in patients with Parkinson's disease: filling the bench-to-bedside gap , 2010, The Lancet Neurology.

[68]  David M. Lovinger,et al.  Neurotransmitter roles in synaptic modulation, plasticity and learning in the dorsal striatum , 2010, Neuropharmacology.

[69]  H. Bergman,et al.  Goal-directed and habitual control in the basal ganglia: implications for Parkinson's disease , 2010, Nature Reviews Neuroscience.

[70]  Anatol C. Kreitzer,et al.  Regulation of parkinsonian motor behaviours by optogenetic control of basal ganglia circuitry , 2010, Nature.

[71]  P. Calabresi,et al.  Inhibition of phosphodiesterases rescues striatal long-term depression and reduces levodopa-induced dyskinesia. , 2011, Brain : a journal of neurology.

[72]  B. Roth,et al.  Transient neuronal inhibition reveals opposing roles of indirect and direct pathways in sensitization , 2010, Nature Neuroscience.

[73]  P. Calabresi,et al.  The Distinct Role of Medium Spiny Neurons and Cholinergic Interneurons in the D2/A2A Receptor Interaction in the Striatum: Implications for Parkinson's Disease , 2011, The Journal of Neuroscience.

[74]  D. Sibley,et al.  Dopamine D2 Receptor Overexpression Alters Behavior and Physiology in Drd2-EGFP Mice , 2011, The Journal of Neuroscience.

[75]  Laurent Venance,et al.  Spike-timing dependent plasticity in striatal interneurons , 2011, Neuropharmacology.

[76]  Kuei Yuan Tseng,et al.  Nitric Oxide–Soluble Guanylyl Cyclase–Cyclic GMP Signaling in the Striatum: New Targets for the Treatment of Parkinson's Disease? , 2011, Front. Syst. Neurosci..

[77]  P. Calabresi,et al.  Dopamine-Dependent Long-Term Depression Is Expressed in Striatal Spiny Neurons of Both Direct and Indirect Pathways: Implications for Parkinson's Disease , 2011, The Journal of Neuroscience.

[78]  A. Pisani,et al.  Homeostatic changes of the endocannabinoid system in Parkinson's disease , 2011, Movement disorders : official journal of the Movement Disorder Society.

[79]  C. Gerfen,et al.  Modulation of striatal projection systems by dopamine. , 2011, Annual review of neuroscience.

[80]  Yvette E. Fisher,et al.  Differential Electrophysiological Changes in Striatal Output Neurons in Huntington's Disease , 2011, The Journal of Neuroscience.

[81]  E. Bézard,et al.  Molecular mechanisms of l-DOPA-induced dyskinesia. , 2011, International review of neurobiology.

[82]  Antonio Daniele,et al.  Treatment of motor and non-motor features of Parkinson's disease with deep brain stimulation , 2012, The Lancet Neurology.

[83]  P. Calabresi,et al.  Rebalance of Striatal NMDA/AMPA Receptor Ratio Underlies the Reduced Emergence of Dyskinesia During D2-Like Dopamine Agonist Treatment in Experimental Parkinson's Disease , 2012, The Journal of Neuroscience.

[84]  S. Fox,et al.  Drug treatments for the neuropsychiatric complications of Parkinson’s disease , 2012, Expert review of neurotherapeutics.

[85]  Anatol C. Kreitzer,et al.  A Comparison of Striatal-Dependent Behaviors in Wild-Type and Hemizygous Drd1a and Drd2 BAC Transgenic Mice , 2012, The Journal of Neuroscience.

[86]  Joshua L. Plotkin,et al.  Strain-Specific Regulation of Striatal Phenotype in Drd2-eGFP BAC Transgenic Mice , 2012, The Journal of Neuroscience.

[87]  Anatol C. Kreitzer,et al.  Distinct roles for direct and indirect pathway striatal neurons in reinforcement , 2012, Nature Neuroscience.

[88]  T. Tkatch,et al.  SK channel modulation rescues striatal plasticity and control over habit in cannabinoid tolerance , 2012, Nature Neuroscience.

[89]  L. Wilbrecht,et al.  Transient stimulation of distinct subpopulations of striatal neurons mimics changes in action value , 2012, Nature Neuroscience.

[90]  Brian N. Mathur,et al.  Endocannabinoid–Dopamine Interactions in Striatal Synaptic Plasticity , 2012, Front. Pharmacol..

[91]  L. Riquelme,et al.  Striatal NMDA receptors gate cortico-pallidal synchronization in a rat model of Parkinson's disease , 2012, Neurobiology of Disease.

[92]  Ian R. Wickersham,et al.  Convergent cortical innervation of striatal projection neurons , 2013, Nature Neuroscience.

[93]  Steven S. Vogel,et al.  Concurrent Activation of Striatal Direct and Indirect Pathways During Action Initiation , 2013, Nature.

[94]  Anatol C. Kreitzer,et al.  Control of Basal Ganglia Output by Direct and Indirect Pathway Projection Neurons , 2013, The Journal of Neuroscience.

[95]  P. Calabresi,et al.  Ischemic-LTP in Striatal Spiny Neurons of both Direct and Indirect Pathway Requires the Activation of D1-Like Receptors and NO/Soluble Guanylate Cyclase/cGMP Transmission , 2013, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[96]  G. Deuschl,et al.  Neurostimulation for Parkinson's disease with early motor complications. , 2013, The New England journal of medicine.

[97]  L. Bour,et al.  Subthalamic nucleus versus globus pallidus bilateral deep brain stimulation for advanced Parkinson's disease (NSTAPS study): a randomised controlled trial , 2013, The Lancet Neurology.

[98]  H. Moore,et al.  Dopamine D2 Receptors Regulate the Anatomical and Functional Balance of Basal Ganglia Circuitry , 2014, Neuron.

[99]  John P. Walsh,et al.  Treadmill exercise reverses dendritic spine loss in direct and indirect striatal medium spiny neurons in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease , 2014, Neurobiology of Disease.

[100]  B. O'dowd,et al.  Heteromeric Dopamine Receptor Signaling Complexes: Emerging Neurobiology and Disease Relevance , 2014, Neuropsychopharmacology.

[101]  David A. Lewis,et al.  Implications for Parkinson ' s Disease , 2022 .